Infinity Pharmacy, the biggest operator of Priceline-branded stores and a key part of Wesfarmers’ healthcare ambitions, ultimately collapsed last year under mounting debts, with dozens of its outlets now being auctioned off. The business had been expanding in a competitive retail health market where margins were tightening and interest costs were rising, putting pressure on operators that relied heavily on borrowed funds to grow.
Correspondence from GCI Funds to Infinity as far back as November 2024 reveals that lenders wanted a formal governance reset and a detailed recovery roadmap. They pressed for an 11-step programme that covered everything from restructuring several debt facilities through to installing a proper board to oversee a divestment strategy, with at least three directors and clear delegation of authority to senior finance leaders. At the same time, the lenders signalled they already viewed Infinity as being in breach of its loan terms, underscoring how fragile the company’s financial position had become.
Infinity’s situation now looks like a cautionary case for other franchise groups and healthcare retailers that combine rapid expansion with complex financing. While stricter oversight, clearer boards and structured debt workouts seem to be gaining favour among lenders, the fallout from this collapse suggests that warning signs can surface long before a formal insolvency process and how those early interventions are handled may shape the survival prospects of large franchise networks.
